Revenue
2022
Lexeo Therapeutics, Inc. (LXEO)
Price—Loading quote
Net income
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | — | — | — | $654,000 |
| Research & development | $63.8M | $74.1M | $53.1M | $49.2M |
| Operating expenses | $109.3M | $105.8M | $68.5M | $61.2M |
| Operating income | −$109.3M | −$105.8M | −$68.5M | −$60.5M |
| EBITDAderived | −$109.0M | −$105.5M | −$68.2M | −$60.4M |
| Net income | −$100.0M | −$98.3M | −$66.4M | −$59.3M |
| Basic EPSper diluted share | -$1.86 | -$3.09 | -$12.40 | -$36.36 |
| Diluted EPSper diluted share | -$1.86 | -$3.09 | -$12.40 | -$36.36 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 18, 2026Form 4 | Otero Jose ManuelChief Operating Officer | SellCommon Stock | 1.3K | $5.07 | $6.6K | 130.1K |
| May 18, 2026Form 4 | Townsend Richard NolanChief Executive Officer | SellCommon Stock | 3.3K | $5.06 | $16.9K | 336.8K |
| Apr 6, 2026Form 4 · 10b5-1 | Townsend Richard NolanChief Executive Officer | SellCommon Stock | 55.0K | $5.69 | $312.9K | 340.1K |
| Feb 18, 2026Form 4 | Otero Jose ManuelChief Operating Officer | SellCommon Stock | 3.0K | $6.40 | $19.3K | 125.5K |
| Feb 18, 2026Form 4 | Townsend Richard NolanChief Executive Officer | SellCommon Stock | 10.2K | $6.38 | $64.9K | 392.5K |